What is Multiple system atrophy?
Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects multiple parts of the nervous system. The condition causes a combination of movement problems similar to Parkinson’s disease, balance and coordination difficulties, and dysfunction of the autonomic nervous system that controls blood pressure, heart rate, and other automatic bodily functions. MSA occurs sporadically, meaning it is not inherited, and affects approximately 3-4 people per 100,000 in the population. The disease typically begins in adulthood and progresses more rapidly than Parkinson’s disease, with patients often experiencing poor response to standard Parkinson’s medications.
Key statistics
| Prevalence: | 3-4 per 100,000 people |
| Age of onset: | 50-60 years (average 55 years) |
| Gender distribution: | Slightly more common in men |
| Survival: | 6-10 years from symptom onset |
Symptoms
Primary symptoms: Orthostatic hypotension, parkinsonism, cerebellar ataxia, autonomic dysfunction, poor levodopa response, urinary incontinence, speech difficulties, sleep disorders.
MSA presents with a complex array of symptoms that can be grouped into three main categories. Parkinsonian symptoms include slowness of movement (bradykinesia), muscle rigidity, tremor, and shuffling gait, though these features typically respond poorly to levodopa treatment, unlike in Parkinson’s disease.
Cerebellar symptoms involve coordination and balance problems, including unsteady walking (ataxia), difficulty with fine motor tasks, slurred speech (dysarthria), and problems with eye movements. Patients may experience frequent falls and difficulty maintaining balance.
Autonomic symptoms are often the most disabling and include orthostatic hypotension (dramatic drop in blood pressure when standing), leading to dizziness, fainting, and falls. Other autonomic features include urinary urgency and incontinence, constipation, sexual dysfunction, excessive sweating or inability to sweat, and difficulty regulating body temperature.
Additional symptoms may include sleep disturbances, particularly REM sleep behavior disorder where patients act out their dreams, depression, anxiety, and cognitive changes that are typically milder than those seen in other neurodegenerative diseases.
Causes and risk factors
MSA is caused by the abnormal accumulation of a protein called alpha-synuclein in specific brain cells called oligodendrocytes, forming structures known as glial cytoplasmic inclusions. This protein buildup leads to progressive damage and death of neurons in multiple brain regions, including areas controlling movement, balance, and autonomic functions.
The condition occurs sporadically, meaning it is not inherited from parents and does not run in families. The exact triggers that cause alpha-synuclein to misfold and accumulate are unknown, though researchers suspect a combination of genetic susceptibility, environmental factors, and aging may play roles.
Risk factors are poorly understood, but age is the primary known factor, with most cases developing after age 50. Some studies suggest possible associations with exposure to certain toxins, metals, or infections, but no definitive environmental causes have been established.
Prevention
Currently, there are no established methods to prevent MSA. Because the condition is sporadic rather than inherited, genetic testing and family screening are not recommended. The unknown cause and lack of identifiable risk factors mean that specific prevention strategies have not been developed.
Research is ongoing to identify potential biomarkers that might detect the disease in its earliest stages, which could eventually lead to preventive interventions. However, no screening programs exist for asymptomatic individuals.
Complications
Without treatment, MSA complications can be severe and life-threatening. Orthostatic hypotension can cause dangerous falls, injuries, and reduced mobility. Progressive swallowing difficulties may lead to aspiration pneumonia, a common cause of death in MSA patients.
Urinary complications include incontinence and retention, potentially requiring catheterization. Sleep disorders can significantly impact quality of life and may contribute to cognitive decline. As the disease progresses, patients typically become increasingly disabled, requiring assistance with daily activities and eventually full-time care.
The rapid progression of MSA often leads to wheelchair dependence within several years of diagnosis. Respiratory complications may develop in advanced stages, and the combination of multiple system failures ultimately proves fatal.
Diagnosis
MSA diagnosis relies primarily on clinical assessment, as no definitive biomarker currently exists. Physicians use established diagnostic criteria that require evidence of autonomic dysfunction plus either parkinsonian or cerebellar features, with poor response to levodopa treatment.
Clinical tests include autonomic function testing to measure blood pressure responses, heart rate variability, and sweating patterns. The head-up tilt table test specifically evaluates orthostatic hypotension. Urodynamic studies assess bladder function.
Imaging studies may show characteristic changes on brain MRI, including the “hot cross bun” sign in the brainstem and atrophy of specific brain regions. DaTscan (dopamine transporter imaging) can help differentiate MSA from other conditions.
Sleep studies may reveal REM sleep behavior disorder, which often precedes other MSA symptoms. Detailed neurological examination assesses movement, balance, coordination, and cognitive function.
The diagnostic journey can be lengthy and challenging, as MSA symptoms often overlap with other neurodegenerative diseases, particularly early in the disease course.
Treatment
No cure exists for MSA, and treatment focuses on managing symptoms and maintaining quality of life. Levodopa may provide modest improvement in parkinsonian symptoms for some patients, though response is typically limited and temporary.
Orthostatic hypotension management includes non-pharmacological approaches like increased salt and fluid intake, compression stockings, and positional maneuvers. Medications include fludrocortisone, midodrine, and droxidopa.
Urinary symptoms may be treated with oxybutynin or tolterodine for overactive bladder, while retention may require intermittent catheterization.
Physical therapy helps maintain mobility and prevent falls. Occupational therapy assists with daily activities and adaptive equipment. Speech therapy addresses communication and swallowing difficulties.
Sleep disorders may respond to melatonin or clonazepam for REM sleep behavior disorder.
Prognosis
MSA has a progressive course with average survival of 6-10 years from symptom onset, though individual variation exists. The disease typically progresses more rapidly than Parkinson’s disease, with patients experiencing increasing disability over time.
Factors associated with faster progression include early onset of autonomic symptoms, poor levodopa response, and cerebellar features. Most patients become wheelchair-dependent within 5-7 years of diagnosis.
Quality of life can be maintained for several years with appropriate symptom management, supportive care, and adaptive strategies. However, the progressive nature of the disease means that independence gradually declines, and most patients eventually require full-time care assistance.
Quality of life
Living with MSA requires significant lifestyle adaptations and support systems. Patients benefit from structured daily routines that accommodate movement difficulties and autonomic symptoms. Home modifications including grab bars, raised toilet seats, and shower chairs improve safety and independence.
Diet modifications may include increased salt intake for blood pressure management and texture modifications for swallowing difficulties. Regular, gentle exercise within individual capabilities helps maintain strength and mobility.
Mental health support is crucial, as depression and anxiety are common. Counseling, support groups, and sometimes antidepressant medications can help. Maintaining social connections and meaningful activities for as long as possible supports emotional well-being.
Caregivers require substantial support and resources, as the care burden increases significantly as the disease progresses.
Pregnancy and fertility
MSA rarely affects women of childbearing age, as onset typically occurs after age 50. For the uncommon cases where pregnancy might be considered, careful medical supervision would be essential due to autonomic dysfunction and medication considerations.
The orthostatic hypotension and other autonomic symptoms could complicate pregnancy, and many MSA medications have unknown safety profiles in pregnancy. Genetic counseling is generally not necessary since MSA is sporadic rather than inherited.
Children
MSA does not occur in children, as it is an adult-onset neurodegenerative disease. However, children of MSA patients may need psychological support and age-appropriate education about their parent’s condition as the disease progresses.
Family counseling can help children understand the progressive nature of the disease and cope with the changing family dynamics as caregiving needs increase.
When to see a doctor
Seek medical evaluation for persistent combinations of movement difficulties, balance problems, and unexplained fainting or dizziness when standing. Early warning signs include frequent falls, urinary incontinence, sleep disturbances with acting out dreams, and poor response to Parkinson’s medications.
Urgent care is needed for severe orthostatic hypotension causing frequent fainting, swallowing difficulties with choking episodes, or respiratory problems. Progressive disability warrants prompt neurological evaluation to optimize symptom management and care planning.
Regional context
Limited data exists on MSA prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or Eastern Mediterranean countries. The condition appears to affect populations worldwide with similar frequency, though comprehensive epidemiological studies are lacking in many regions.
Healthcare providers and researchers in these areas are encouraged to contribute regional data to the Global Medical Journal to improve understanding of MSA distribution and characteristics across different populations.
Research and clinical trials
Current research focuses on disease biomarkers, neuroprotective therapies, and symptom management strategies. Studies are investigating alpha-synuclein-targeting treatments, stem cell therapies, and novel approaches to autonomic dysfunction.
Recent breakthroughs include improved understanding of MSA pathology and development of better diagnostic criteria. Promising research areas include immunotherapies targeting alpha-synuclein and gene therapy approaches.
Clinical trials can be found at ClinicalTrials.gov, with studies examining both symptomatic treatments and potential disease-modifying therapies. Patients are encouraged to discuss trial participation with their healthcare providers.
Frequently asked questions
How is MSA different from Parkinson’s disease?
MSA progresses more rapidly than Parkinson’s disease, includes prominent autonomic symptoms like orthostatic hypotension, and responds poorly to levodopa treatment. MSA also involves cerebellar symptoms affecting balance and coordination.
Is MSA hereditary?
No, MSA is sporadic and not inherited. It does not run in families, and genetic testing is not recommended for family members.
Can MSA be cured?
Currently, no cure exists for MSA. Treatment focuses on managing symptoms and maintaining quality of life for as long as possible.
What is the life expectancy with MSA?
Average survival is 6-10 years from symptom onset, though individual experiences vary. The disease typically progresses more rapidly than other neurodegenerative conditions.
What support is available for MSA patients and families?
The MSA Coalition provides resources, support groups, and advocacy. Local neurologists, palliative care teams, and social services can help coordinate comprehensive care.
Support and resources
International organizations:
– MSA Coalition: https://www.multiplesystematrophy.org
– Orphanet: https://www.orpha.net
– National Organization for Rare Disorders (NORD): https://rarediseases.org
– EURORDIS: https://www.eurordis.org
– International Parkinson and Movement Disorder Society: https://www.movementdisorders.org
Research and information:
– ClinicalTrials.gov: https://clinicaltrials.gov
– MSA Research Center: Various academic institutions provide specialized care and research opportunities
Related conditions
Parkinson’s disease
Progressive supranuclear palsy
Dementia with Lewy bodies
Cerebellar ataxia
Pure autonomic failure
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Multiple system atrophy.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/multiple-system-atrophy/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?